AI In Drug Screening Market Size 2025-2029
The ai in drug screening market size is forecast to increase by USD 3.0 billion, at a CAGR of 41.1% between 2024 and 2029.
The imperative to shorten drug discovery timelines and reduce costs is a primary factor driving the global AI in drug screening market. The proliferation of generative AI is a significant trend, enabling the in-silico generation and screening of vast chemical libraries, which profoundly accelerates the initial phases of research. This approach allows for the design of drug candidates from the ground up, predicting their efficacy and potential toxicity with greater precision. This evolution in the drug screening market involves a shift toward predictive methodologies, integrating artificial intelligence in drug discovery to create novel therapeutic possibilities and streamline development workflows, which is essential for advancing areas like ai in precision medicine and generative ai in healthcare.However, the scarcity of high-quality, large-scale, and readily accessible datasets poses a considerable challenge to creating comprehensive training sets for robust AI model training. Incomplete or erroneous data can introduce bias into AI models, leading to unreliable predictions and misdirected research efforts in predictive toxicology. The proprietary nature of much of this information also limits the collective knowledge base available for training more powerful and generalizable models. This data bottleneck impacts the full potential of ai-powered platforms and hinders progress in the broader applied ai in healthcare landscape, including advancements in ai in cancer diagnostics and drug-target interactions, despite ongoing efforts.
What will be the Size of the AI In Drug Screening Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The global AI in drug screening market is characterized by a fundamental shift toward data-driven drug discovery, where AI-powered platforms are becoming central to R&D strategy. These systems deploy advanced machine learning algorithms and deep learning models to enable comprehensive chemical space exploration, accelerating hit and lead discovery. The integration of artificial intelligence in drug discovery is moving the industry beyond traditional experimental limitations. This evolution facilitates a more predictive and efficient approach to identifying viable therapeutic candidates, with a clear focus on leveraging complex datasets for molecular structure analysis and enhancing outcomes in the broader drug screening market.Key applications in preclinical testing and clinical trials are being redefined through improved toxicity prediction and the use of generative AI models for de novo drug design. The focus on optimizing pharmacokinetic properties and pharmacodynamic properties early in the pipeline is critical for reducing attrition rates. The application of AI in predictive toxicology provides deeper insights into compound safety, while generative ai in personalized medicine allows for the creation of therapies tailored to specific patient populations. These advancements in predictive toxicology and therapeutic design are instrumental in making drug development more targeted and successful, driving progress in fields such as AI in oncology.The effectiveness of these computational methods hinges on robust model validation and the growing adoption of explainable AI (XAI) to demystify black box algorithms. The analysis of multi-omics data and the use of biomedical knowledge graphs provide a more holistic understanding of disease biology. As the field matures, establishing regulatory trust through transparent and interpretable models is paramount. This progress supports the development of more accurate AI-driven tools for drug-target interactions and target identification, fostering greater confidence and adoption across the pharmaceutical landscape and pushing the boundaries of what is possible in applied AI in healthcare.
How is this AI In Drug Screening Industry segmented?
The ai in drug screening industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Application
- Type
- Preclinical testing
- Clinical trials
- Toxicity prediction
- Virtual screening
- End-user
- Pharmaceutical companies
- Biotechnology firms
- Research institutes
- Contract research organization
- Geography
- North America
- Europe
- Germany
- UK
- France
- The Netherlands
- Spain
- Italy
- Russia
- Asia
- Rest of World (ROW)
By Application Insights
The drug repurposing segment is estimated to witness significant growth during the forecast period.
The strategy of drug repurposing leverages the established safety profiles of existing drugs to significantly reduce development timelines and costs. AI algorithms and machine learning models are instrumental in this process, as they can systematically scan extensive databases to identify novel drug-disease associations and drug-target interactions that are often missed by traditional experimental methods. This computational approach streamlines the discovery of new therapeutic uses for approved or investigational compounds.
Advanced deep learning models are employed to predict new interactions and elucidate the underlying mechanisms of action for repurposed drug candidates. This application is a significant market component, accounting for approximately 40% of activity, as it efficiently identifies new uses for existing therapies. Furthermore, generative AI models can design novel molecules with improved efficacy and reduced toxicity by using the chemical scaffolds of existing drugs, further enhancing the potential of this efficient drug discovery strategy.
Request Free Sample
The Drug repurposing segment was valued at USD 20.60 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 35.7% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The North America region holds a preeminent position in the market, a status supported by robust research and development expenditure, a high concentration of leading pharmaceutical and biotechnology companies, and a vibrant AI technology ecosystem. This leadership is reflected in its contribution to market expansion, with the region accounting for over 35% of the incremental growth. The area benefits from substantial government and venture capital support, which fuels the growth of pioneering startups and fosters an environment of innovation in drug discovery development.
A deeply collaborative spirit characterizes the North America market, where strategic partnerships combine extensive pharmaceutical data with advanced algorithms and cutting-edge AI models to streamline the drug development lifecycle. The proactive regulatory environment further strengthens its position by reducing barriers to market entry and encouraging the adoption of AI-powered methodologies. This synergy between industry, finance, and regulation creates a mature and dynamic landscape poised for continued leadership and growth in the application of AI to drug screening.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global AI in drug screening market is experiencing significant growth, driven by the imperative to accelerate therapeutic discovery. Companies are increasingly using AI for identifying novel drug targets by employing sophisticated AI-driven analysis of genomic data and natural language processing in biomarker discovery. This early-stage process is further enhanced by robust AI-powered target identification and validation. Once targets are confirmed, deep learning for virtual screening and generative AI for de novo molecule design are utilized to explore vast chemical libraries. The industry is also focused on automating high-throughput screening with AI and leveraging AI for designing novel biologic candidates, fundamentally changing how initial leads are found and created.Following discovery, AI platforms for lead optimization enable superior multi-parameter optimization in drug design. Key predictive capabilities include accurately predicting drug-target binding affinity, utilizing machine learning for predictive toxicology, and deploying AI models for ADMET property prediction. These advancements drastically shorten AI in preclinical development timelines. The overarching goal is using AI to reduce clinical trial failures and finding new applications via AI for repurposing existing drugs. For market approval, building explainable AI for regulatory trust is crucial for validating computational models in drug submissions. Finally, the rise of AI in personalized medicine development and secure data sharing through federated learning for health data are paving the way for next-generation treatments.
What are the key market drivers leading to the rise in the adoption of AI In Drug Screening Industry?
- A significant factor shaping the market is the critical need to shorten the lengthy and expensive timelines inherent in traditional drug discovery and development.
The critical need to shorten pharmaceutical R&D timelines and curtail associated costs is a major influence on the market. By leveraging sophisticated algorithms, AI platforms analyze vast biological and chemical datasets with a speed and accuracy that manual efforts cannot match. This capability enables the rapid identification of promising drug candidates through in-silico methods and the early elimination of those likely to fail, optimizing resource allocation. The market opportunity is significant, with some analyses attributing over 35% of the potential growth to specific advanced economies. This data-driven approach, which includes advanced molecular structure analysis and chemical space exploration, is revolutionizing the preclinical phase, helping to mitigate substantial financial losses from unsuccessful research avenues and accelerate therapeutic development through enhanced target identification.The growth in strategic collaborations between pharmaceutical corporations, biotechnology firms, and specialized AI technology providers is another key driver. These alliances create powerful synergies by combining deep domain expertise in biology and clinical development with advanced computational capabilities and expertise in data science. The resulting partnerships accelerate discovery and unlock new therapeutic possibilities that would be difficult to achieve independently. This collaborative model is crucial, as major end-users such as large pharmaceutical companies represent nearly 39% of the market's activity. These integrated, long-term collaborations focus on co-developing novel AI-powered platforms and applying them to specific disease areas, marking a fundamental shift from siloed research to a more networked and innovative drug discovery paradigm using techniques like biomedical knowledge graphs.
What are the market trends shaping the AI In Drug Screening Industry?
- The increasing adoption of generative AI is a key development, profoundly accelerating the drug screening process by enabling the novel creation of potential therapeutic molecules.
A paramount trend is the rapid integration of generative AI, which creates novel outputs such as new molecules with desired properties, rather than only analyzing existing data. This capability is profoundly accelerating the initial phases of drug discovery by enabling in silico generation and screening of vast chemical libraries. This approach significantly curtails the time and resources traditionally expended on high-throughput screening in wet laboratories. The technology is leveraged to design drug candidates, predict their efficacy and toxicity, and repurpose existing drugs. This is particularly impactful in areas like drug repurposing, which constitutes over 40% of the market by application. This global shift positions generative ai in healthcare as a cornerstone of modern drug screening and artificial intelligence in drug discovery.The increasing complexity of AI models has led to the 'black box' problem, making explainable AI (XAI) a critical trend for regulatory trust and adoption. XAI aims to make the decision-making processes of sophisticated algorithms more transparent and interpretable to researchers, clinicians, and regulatory bodies. For the highly regulated pharmaceutical industry, the ability to comprehend and validate the reasoning behind an AI-driven prediction is a necessity for ensuring safety and efficacy. This push for transparency is particularly strong in well-regulated geographies, with certain developed regions accounting for over 28% of the market opportunity. This trend toward model explainability not only aids in regulatory compliance but also fosters greater confidence among scientists, accelerating the entire drug discovery and development pipeline for applications in ai in precision medicine.
What challenges does the AI In Drug Screening Industry face during its growth?
- A major impediment to market expansion is the persistent difficulty in accessing high-quality, large-scale, and shareable datasets required for effective AI model training.
A primary challenge is the scarcity of high-quality, large-scale, and accessible datasets, as AI models require vast and diverse data for effective training. This information is often fragmented across disparate sources and stored in non-standardized formats, creating significant data silos and impeding the creation of comprehensive datasets needed for robust AI model training. Furthermore, the proprietary nature of much of this data presents a hurdle, as competitive concerns limit sharing and restrict the collective knowledge base for training more powerful models. This data challenge is pronounced in preclinical testing, a segment that represents approximately 38% of the market, where high-quality historical data is essential for building predictive models for applications like predictive toxicology and molecular structure analysis.The substantial financial investment and resource allocation required for successful AI implementation represent another major challenge. Initial setup costs, which include high-performance computing infrastructure and specialized software licensing, can be prohibitive for smaller organizations. Beyond capital outlay, significant ongoing operational expenses for data storage, management, and system maintenance add to the financial burden. While the market shows strong potential, with some regions projected to contribute nearly 25% of the growth, the significant financial and human resource investment required presents a barrier to entry. This is compounded by a pronounced shortage of professionals with the requisite interdisciplinary expertise, blending pharmaceutical sciences with advanced data science and machine learning skills, creating a competitive and costly recruitment landscape.
Exclusive Customer Landscape
The ai in drug screening market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the ai in drug screening market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, ai in drug screening market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Anima Biotech - The core offerings in this market center on advanced AI-powered platforms that facilitate drug screening and discovery. These systems utilize a range of techniques, including machine learning, deep learning, and generative AI, to analyze complex biomedical data. Key functionalities include the identification of novel drug targets, the de novo design of small molecules and biologics, and the prediction of compound efficacy and safety profiles. By leveraging physics-based models, knowledge graphs, and large-scale data analysis, these solutions aim to accelerate the entire drug discovery pipeline, from initial hit identification to lead optimization and preclinical candidate selection.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Anima Biotech
- Atomwise Inc.
- BenevolentAI
- BioXcel Therapeutics Inc.
- Charles River Laboratories International Inc.
- Deep Genomics Inc.
- DenovAI
- Evotec SE
- Exscientia plc
- Generate Biomedicines
- Iktos
- Insilico Medicine
- insitro
- Isomorphic Labs
- Schrodinger Inc.
- WuXi AppTec Co. Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Ai In Drug Screening Market
In May 2024, Sanofi, Formation Bio, and OpenAI announced a first-of-its-kind partnership to build AI-powered software to accelerate drug development, leveraging proprietary data and advanced AI models.In April 2024, Xaira Therapeutics launched with over USD 1 billion in funding to advance its work in AI-driven drug discovery and development, aiming to transform the pharmaceutical industry.In January 2024, Isomorphic Labs announced major strategic collaborations with both Eli Lilly and Novartis, utilizing its advanced AI platform to discover small molecule therapeutics against multiple disease targets.
Research Analyst Overview
The global AI in drug screening market is characterized by a fundamental shift toward integrated, data-driven drug discovery. The evolution from conventional high-throughput screening to sophisticated in-silico methods is reshaping the entire development pipeline. AI-powered platforms are becoming central to achieving end-to-end drug discovery, employing advanced machine learning algorithms and deep learning models. These computational biology approaches accelerate critical phases, including initial target identification, drug repurposing, and subsequent lead optimization. The application of virtual screening enhances the precision of preclinical testing and clinical trials design, enabling a more dynamic exploration of chemical libraries. This transformation is not merely an augmentation but a re-engineering of traditional pharmaceutical research, focusing on predictive accuracy and operational efficiency from hit and lead discovery to final model validation.The operational context of this market is advancing through the deployment of more complex predictive tools, with industry expectations suggesting a potential expansion of market accessibility by approximately 45%. The utilization of generative AI models for de novo drug design and chemical space exploration marks a significant development. Techniques such as protein structure prediction, molecular dynamics, and molecular docking are refined for enhanced analysis of drug-target interactions and ligand-receptor docking. A critical focus is on improving predictive toxicology and the early assessment of ADMET properties, including pharmacokinetic properties and pharmacodynamic properties. The integration of biomedical knowledge graphs with multi-omics data analysis facilitates deeper insights for biomarker discovery, with explainable AI (XAI) becoming more crucial for regulatory compliance.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled AI In Drug Screening Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
303
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 41.1%
|
|
Market growth 2024-2029
|
USD 3.0 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
35.4%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, The Netherlands, Spain, Italy, Russia, China, Japan, India, South Korea, Singapore, Indonesia, Thailand, Australia, Brazil, South Africa, UAE, Saudi Arabia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this AI In Drug Screening Market Research and Growth Report?
- CAGR of the AI In Drug Screening industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the ai in drug screening market growth of industry companies
We can help! Our analysts can customize this ai in drug screening market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global AI In Drug Screening Market 2019 - 2023
- Historic Market Size - Data Table on Global AI In Drug Screening Market 2019 - 2023 ($ billion)
- 5.2 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.3 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.4 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Five Forces Analysis
- 6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
7 Market Segmentation by Application
- 7 Market Segmentation by Application
- 7.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 7.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 7.3 Drug repurposing - Market size and forecast 2024-2029
- Chart on Drug repurposing - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug repurposing - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug repurposing - Year-over-year growth 2024-2029 (%)
- Data Table on Drug repurposing - Year-over-year growth 2024-2029 (%)
- 7.4 Target identification - Market size and forecast 2024-2029
- Chart on Target identification - Market size and forecast 2024-2029 ($ billion)
- Data Table on Target identification - Market size and forecast 2024-2029 ($ billion)
- Chart on Target identification - Year-over-year growth 2024-2029 (%)
- Data Table on Target identification - Year-over-year growth 2024-2029 (%)
- 7.5 Lead optimization - Market size and forecast 2024-2029
- Chart on Lead optimization - Market size and forecast 2024-2029 ($ billion)
- Data Table on Lead optimization - Market size and forecast 2024-2029 ($ billion)
- Chart on Lead optimization - Year-over-year growth 2024-2029 (%)
- Data Table on Lead optimization - Year-over-year growth 2024-2029 (%)
- 7.6 Biomarker discovery - Market size and forecast 2024-2029
- Chart on Biomarker discovery - Market size and forecast 2024-2029 ($ billion)
- Data Table on Biomarker discovery - Market size and forecast 2024-2029 ($ billion)
- Chart on Biomarker discovery - Year-over-year growth 2024-2029 (%)
- Data Table on Biomarker discovery - Year-over-year growth 2024-2029 (%)
- 7.7 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
8 Market Segmentation by Type
- 8 Market Segmentation by Type
- 8.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 8.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 8.3 Preclinical testing - Market size and forecast 2024-2029
- Chart on Preclinical testing - Market size and forecast 2024-2029 ($ billion)
- Data Table on Preclinical testing - Market size and forecast 2024-2029 ($ billion)
- Chart on Preclinical testing - Year-over-year growth 2024-2029 (%)
- Data Table on Preclinical testing - Year-over-year growth 2024-2029 (%)
- 8.4 Clinical trials - Market size and forecast 2024-2029
- Chart on Clinical trials - Market size and forecast 2024-2029 ($ billion)
- Data Table on Clinical trials - Market size and forecast 2024-2029 ($ billion)
- Chart on Clinical trials - Year-over-year growth 2024-2029 (%)
- Data Table on Clinical trials - Year-over-year growth 2024-2029 (%)
- 8.5 Toxicity prediction - Market size and forecast 2024-2029
- Chart on Toxicity prediction - Market size and forecast 2024-2029 ($ billion)
- Data Table on Toxicity prediction - Market size and forecast 2024-2029 ($ billion)
- Chart on Toxicity prediction - Year-over-year growth 2024-2029 (%)
- Data Table on Toxicity prediction - Year-over-year growth 2024-2029 (%)
- 8.6 Virtual screening - Market size and forecast 2024-2029
- Chart on Virtual screening - Market size and forecast 2024-2029 ($ billion)
- Data Table on Virtual screening - Market size and forecast 2024-2029 ($ billion)
- Chart on Virtual screening - Year-over-year growth 2024-2029 (%)
- Data Table on Virtual screening - Year-over-year growth 2024-2029 (%)
- 8.7 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by End-user
- 9 Market Segmentation by End-user
- 9.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 9.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 9.3 Pharmaceutical companies - Market size and forecast 2024-2029
- Chart on Pharmaceutical companies - Market size and forecast 2024-2029 ($ billion)
- Data Table on Pharmaceutical companies - Market size and forecast 2024-2029 ($ billion)
- Chart on Pharmaceutical companies - Year-over-year growth 2024-2029 (%)
- Data Table on Pharmaceutical companies - Year-over-year growth 2024-2029 (%)
- 9.4 Biotechnology firms - Market size and forecast 2024-2029
- Chart on Biotechnology firms - Market size and forecast 2024-2029 ($ billion)
- Data Table on Biotechnology firms - Market size and forecast 2024-2029 ($ billion)
- Chart on Biotechnology firms - Year-over-year growth 2024-2029 (%)
- Data Table on Biotechnology firms - Year-over-year growth 2024-2029 (%)
- 9.5 Research institutes - Market size and forecast 2024-2029
- Chart on Research institutes - Market size and forecast 2024-2029 ($ billion)
- Data Table on Research institutes - Market size and forecast 2024-2029 ($ billion)
- Chart on Research institutes - Year-over-year growth 2024-2029 (%)
- Data Table on Research institutes - Year-over-year growth 2024-2029 (%)
- 9.6 Contract research organization - Market size and forecast 2024-2029
- Chart on Contract research organization - Market size and forecast 2024-2029 ($ billion)
- Data Table on Contract research organization - Market size and forecast 2024-2029 ($ billion)
- Chart on Contract research organization - Year-over-year growth 2024-2029 (%)
- Data Table on Contract research organization - Year-over-year growth 2024-2029 (%)
- 9.7 Market opportunity by End-user
- Market opportunity by End-user ($ billion)
- Data Table on Market opportunity by End-user ($ billion)
10 Customer Landscape
- 10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 11.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 11.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 11.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 11.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 11.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 11.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 11.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 11.4.4 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 11.4.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 11.4.6 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 11.4.7 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 11.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 11.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 11.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 11.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 11.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 11.5.5 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 11.5.6 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 11.5.7 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 11.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 11.6.1 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 11.6.2 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 11.6.3 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 11.6.4 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 11.6.5 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 11.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 11.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
12 Drivers, Challenges, and Opportunity
- 12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Rising imperative to curtail drug discovery timelines and costs
- Increasing frequency of cross-industry collaborations and strategic partnerships
- Continuous advancements in AI technologies
- 12.2 Market challenges
- Data accessibility, quality, and sharing
- High cost and resource intensiveness of AI implementation
- Evolving regulatory landscape and model validation
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Proliferation of generative AI in accelerating drug screening
- Imperative of explainable AI for regulatory trust and adoption
- AI-powered target identification and validation as foundational strategy
13 Competitive Landscape
- 13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14 Competitive Analysis
- 14.1 Companies profiled
- 14.2 Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 Anima Biotech
- Anima Biotech - Overview
- Anima Biotech - Product / Service
- Anima Biotech - Key offerings
- SWOT
- 14.5 Atomwise Inc.
- Atomwise Inc. - Overview
- Atomwise Inc. - Product / Service
- Atomwise Inc. - Key offerings
- SWOT
- 14.6 BenevolentAI
- BenevolentAI - Overview
- BenevolentAI - Product / Service
- BenevolentAI - Key offerings
- SWOT
- 14.7 BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. - Overview
- BioXcel Therapeutics Inc. - Product / Service
- BioXcel Therapeutics Inc. - Key offerings
- SWOT
- 14.8 Charles River Laboratories International Inc.
- Charles River Laboratories International Inc. - Overview
- Charles River Laboratories International Inc. - Business segments
- Charles River Laboratories International Inc. - Key offerings
- Charles River Laboratories International Inc. - Segment focus
- SWOT
- 14.9 Deep Genomics Inc.
- Deep Genomics Inc. - Overview
- Deep Genomics Inc. - Product / Service
- Deep Genomics Inc. - Key offerings
- SWOT
- 14.10 Evotec SE
- Evotec SE - Overview
- Evotec SE - Business segments
- Evotec SE - Key news
- Evotec SE - Key offerings
- Evotec SE - Segment focus
- SWOT
- 14.11 Exscientia plc
- Exscientia plc - Overview
- Exscientia plc - Product / Service
- Exscientia plc - Key offerings
- SWOT
- 14.12 Generate Biomedicines
- Generate Biomedicines - Overview
- Generate Biomedicines - Product / Service
- Generate Biomedicines - Key offerings
- SWOT
- 14.13 Iktos
- Iktos - Overview
- Iktos - Product / Service
- Iktos - Key offerings
- SWOT
- 14.14 Insilico Medicine
- Insilico Medicine - Overview
- Insilico Medicine - Product / Service
- Insilico Medicine - Key offerings
- SWOT
- 14.15 insitro
- insitro - Overview
- insitro - Product / Service
- insitro - Key offerings
- SWOT
- 14.16 Isomorphic Labs
- Isomorphic Labs - Overview
- Isomorphic Labs - Product / Service
- Isomorphic Labs - Key offerings
- SWOT
- 14.17 Schrodinger Inc.
- Schrodinger Inc. - Overview
- Schrodinger Inc. - Business segments
- Schrodinger Inc. - Key offerings
- Schrodinger Inc. - Segment focus
- SWOT
- 14.18 WuXi AppTec Co. Ltd.
- WuXi AppTec Co. Ltd. - Overview
- WuXi AppTec Co. Ltd. - Business segments
- WuXi AppTec Co. Ltd. - Key offerings
- WuXi AppTec Co. Ltd. - Segment focus
- SWOT
15 Appendix
- 15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.5 Data procurement
- 15.6 Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
